- Home
- / Stemline Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Stemline Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$11.8
2020-06-15
Market Capitalization
$621.2 M
2020-06-15
Revenue
$500 K
FY, 2018
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 500.0K | ||||||
| Cost of goods sold | 4.9M | ||||||
| General and administrative expense | 7.9M | 8.1M | 8.8M | 12.1M | 19.2M | 39.1M | 66.8M |
| Operating expense total | 24.1M | 29.3M | 38.3M | 39.9M | 69.5M | 86.8M | 117.6M |
| EBIT | (24.0M) | (29.0M) | (37.6M) | (38.9M) | (68.6M) | (86.3M) | (79.2M) |
| EBIT margin, % | -17257.3% | ||||||
| Interest income | 19.1K | 156.3K | 387.9K | 545.7K | 736.3K | 1.3M | 2.5M |
| Pre tax profit | (38.3M) | (67.8M) | (85.0M) | (76.8M) | |||
| Income tax expense | (11.7M) | (16.6M) | (21.4M) | (25.3K) | (25.6K) | ||
| Net Income | (24.2M) | (28.8M) | (37.2M) | (38.3M) | (67.8M) | (85.0M) | (76.8M) |